Literature DB >> 1951864

Lymphoproliferative responses to synthetic peptides from merozoite ring-infected erythrocyte surface antigen and circumsporozoite protein: a longitudinal study during a falciparum malaria episode.

C Chougnet1, J P Lepers, P Astagneau, M D Rason, J Savel, P Deloron.   

Abstract

Proliferative responses of peripheral blood lymphocytes to synthetic peptides representing major epitopes of two malaria antigens (the merozoite ring-infected erythrocyte surface antigen and the sporozoite circumsporozoite protein) were investigated in Madagascar during a clinical Plasmodium falciparum episode. Thirty-seven patients greater than 10 years of age were enrolled at the beginning of the malaria transmission season and followed for four weeks. At enrollment, when the subjects presented with an acute infection, lymphocytes recovered from approximately 30% of them proliferated after peptide stimulation. These proliferative responses decreased sharply one and two weeks after treatment, with less than 10% responding to each peptide. Four weeks after treatment, the responses were only partially restored. The amplitude of these variations was not related to the initial parasitemia. At the individual level, proliferative response to each peptide varied greatly during the followup period, and this variation was unrelated to the presence of parasites in the blood.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1951864     DOI: 10.4269/ajtmh.1991.45.560

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  7 in total

1.  Low prevalence of antibodies to preerythrocytic but not blood-stage Plasmodium falciparum antigens in an area of unstable malaria transmission compared to prevalence in an area of stable malaria transmission.

Authors:  Gregory S Noland; Brett Hendel-Paterson; Xinan M Min; Ann M Moormann; John M Vulule; David L Narum; David E Lanar; James W Kazura; Chandy C John
Journal:  Infect Immun       Date:  2008-09-22       Impact factor: 3.441

2.  Lymphocyte response in vitro to Plasmodium falciparum merozoite antigens in donors from a holoendemic area.

Authors:  A Dieye; H G Heidrich; C Rogier; J F Trape; P Launois; A A Holder; J L Sarthou
Journal:  Parasitol Res       Date:  1993       Impact factor: 2.289

3.  Differential cellular recognition of antigens during acute Plasmodium falciparum and Plasmodium vivax malaria.

Authors:  Ervi Salwati; Gabriela Minigo; Tonia Woodberry; Kim A Piera; Harini D de Silva; Enny Kenangalem; Emiliana Tjitra; Ross L Coppel; Ric N Price; Nicholas M Anstey; Magdalena Plebanski
Journal:  J Infect Dis       Date:  2011-04-15       Impact factor: 5.226

4.  Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens.

Authors:  Gregory S Noland; Paul Jansen; John M Vulule; Gregory S Park; Bartholomew N Ondigo; James W Kazura; Ann M Moormann; Chandy C John
Journal:  Acta Trop       Date:  2014-10-24       Impact factor: 3.112

5.  Antibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.

Authors:  Chandy C John; Aaron J Tande; Ann M Moormann; Peter O Sumba; David E Lanar; Xinan M Min; James W Kazura
Journal:  J Infect Dis       Date:  2008-02-15       Impact factor: 5.226

6.  Antibodies to the Plasmodium falciparum antigens circumsporozoite protein, thrombospondin-related adhesive protein, and liver-stage antigen 1 vary by ages of subjects and by season in a highland area of Kenya.

Authors:  Chandy C John; Joseph S Zickafoose; P Odada Sumba; Christopher L King; James W Kazura
Journal:  Infect Immun       Date:  2003-08       Impact factor: 3.441

7.  Plasmodium falciparum immunodominant IgG epitopes in subclinical malaria.

Authors:  Isabel G Azcárate; Patricia Marín-García; Paloma Abad; Susana Pérez-Benavente; Estela Paz-Artal; Pedro A Reche; Julius N Fobil; José M Rubio; Amalia Diez; Antonio Puyet; José M Bautista
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.